In vivo and in vitro protective effects of shengmai injection against doxorubicin-induced cardiotoxicity
Context Shengmai injection (SMI) has been used to treat heart failure.Objective This study determines the molecular mechanisms of SMI against cardiotoxicity caused by doxorubicin (DOX).Materials and methods In vivo, DOX (15 mg/kg) was intraperitoneally injected in model, Dex (dexrazoxane), SMI-L (2....
Main Authors: | Peng Zhou, Ge Gao, Chun-chun Zhao, Jing-ya Li, Jian-fei Peng, Shu-shu Wang, Rui Song, Hui Shi, Liang Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2022.2046801 |
Similar Items
-
Mesenchymal Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Cardiotoxicity
by: Sawdah A. Ali, et al.
Published: (2024-01-01) -
p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act
by: Yuanfang Guo, et al.
Published: (2023-05-01) -
Dimethyl Fumarate Ameliorates Doxorubicin-Induced Cardiotoxicity By Activating the Nrf2 Pathway
by: Xiaoliang Hu, et al.
Published: (2022-04-01) -
PEG-modified carbon-based nanoparticles as tumor-targeted drug delivery system reducing doxorubicin-induced cardiotoxicity
by: Lide Wang, et al.
Published: (2023-12-01) -
Synthetic antioxidant TS-13 reduces doxorubicin cardiotoxicity
by: E. B. Menshchikova, et al.
Published: (2023-10-01)